DelveInsight’s “Cytomegalovirus (CMV) Infection Pipeline Insights, 2021” report provides in-depth analysis of the current clinical development landscape and future growth opportunities for the Cytomegalovirus (CMV) Infection industry. The disease description and Cytomegalovirus (CMV) Infection treatment guidelines are included in a clear image of the Cytomegalovirus (CMV) Infection pipeline landscape.
Some of the Key Highlights from the Cytomegalovirus Infection Pipeline Report
Synklino, SpyBiotech, VBI Vaccines, Microbiotix, Nobelpharma, Moderna, Takeda, and others are among the companies developing new drug candidates to improve the Cytomegalovirus Infection pipeline landscape.
Emerging therapy including Maribavir is in Phase III trials for Cytomegalovirus Infection whereas therapies including mRNA-1647 and NPC-21 are in the Phase II trials of development for Cytomegalovirus Infection.
Some Cytomegalovirus Infection pipeline therapies such as VBI-1501 and MBX-400 are in the early stage of development i.e Phase I of clinical trials.
There are some Cytomegalovirus Infection therapies also, such as SYN002 and Cytomegalovirus vaccine which are still in the preclinical stage.
For more information request sample @ Cytomegalovirus Infection Pipeline Insights
Cytomegalovirus Infection: Disease Overview
Infection with the Cytomegalovirus (CMV) is very common. CMV is easily transmitted via the saliva or other bodily fluids of an infected individual. It has nothing to do with the herpes virus, which causes cold sores. There are various types of Cytomegalovirus Infection:
Cytomegalovirus Infection: Symptoms
General symptoms of Primary CMV:
Symptoms of Congenital CMV:
Small size or low birth weight
Yellow skin or eyes (jaundice)
Swollen liver and spleen
Small head (microcephaly)
Cytomegalovirus Infection: Treatment
In most cases, tre atment is not needed for healthy children and adults. CMV mononucleosis in healthy adults typically goes away without treatment. When a newborn or someone with a compromised immune system develops signs of CMV infection, they need to be treated. The type of treatment is determined by the severity of the signs and symptoms. The most popular form of treatment is antiviral medication.
Learn more about CMV @ Cytomegalovirus Infection Causes, Diagnosis and Treatment Landscape
Cytomegalovirus Infection Pipeline Analysis: Drug Profile
mRNA-1647 is a vaccine that combines six mRNAs encoding two antigens into a single vaccine to protect against CMV infection. Five of the six mRNAs encode CMV pentamer complex subunits, while one mRNA encodes the glycoprotein B (gB) protein, both of which are immunogenic. CMV entry into a variety of cells, including epithelial cells, is dependent on the pentamer complex, while gB is required for entry into all susceptible cells, including fibroblasts. A vaccine that induces an immune response to both pentamer and gB could prevent CMV from infecting a variety of target cell types, preventing both primary and congenital infections.
Cytomegalovirus Infection Pipeline Therapies and Key Companies
VBI-1501: VBI Vaccines
Cytomegalovirus vaccine: SpyBiotech
Cytomegalovirus Infection Therapeutics Assessment
By Product Type
By Route of Administration
By Molecule Type
Stem Cell Therapy
By Mechanism of Action
Scope of the Report
CMV Key Players: Synklino, SpyBiotech, VBI Vaccines, Microbiotix, Nobelpharma, Moderna, Takeda, among others
CMV Pipeline Therapies: Maribavir, mRNA-1647, NPC-21, VBI-1501, MBX-400, SYN002, Cytomegalovirus vaccine, others
Table of Contents
CMV Infection: Overview
CMV Infection- Analytical Perspective In-depth Commercial Assessment
CMV Infection: Pipeline Therapeutics
CMV Infection: Late Stage Products (Phase III)
CMV Infection: Mid Stage Products (Phase II)
CMV Infection: Early Stage Products (Phase I)
CMV Infection: Preclinical Stage Products
CMV Infection: Therapeutic Assessment
CMV Infection: Inactive Products
CMV Infection: Company-University Collaborations (Licensing/Partnering) Analysis
CMV Infection Key Companies
CMV Infection Key Products
CMV Infection- Unmet Needs
CMV Infection- Market Drivers and Barriers
CMV Infection- Future Perspectives and Conclusion
CMV Infection Analyst Views
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts
Key Questions Answered in the Cytomegalovirus Infection Report
What are the options for treating Cytomegalovirus infection?
How many firms are working on therapies for Cytomegalovirus Infection?
What are the most common therapies developed by these firms?
What is the total number of Cytomegalovirus Infection therapies developed by each company?
How many new Cytomegalovirus Infection treatments are being established for Cytomegalovirus Infection in its early, middle, and late stages?
How many of the pipeline medications are available as monotherapies or in conjunction with other treatments?
What are the most significant industry-industry and industry-academy partnerships, mergers and acquisitions, and significant licencing practises that will have an effect on Cytomegalovirus Infection?
Cyclin-Dependent Kinase Inhibitor Pipeline Insights
Get comprehensive analysis of Cyclin-Dependent Kinase Inhibitor pipeline therapies and key companies including Roche, Teijin Pharma, Cyclacel Pharmaceuticals, Bayer Schering Pharma, Merck & Co, Astex Therapeutics, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States